Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, Robaczyk MG, Rasmussen ÅK, Feldt-Rasmussen U, Thomsen RW, Søndergaard E, Poulsen PL (2021) Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: A population-based study. J Clin Endocrinol Metab 106:e2251–e2261. https://doi.org/10.1210/clinem/dgaa965

Article  Google Scholar 

Juhlin CC (2021) Challenges in paragangliomas and pheochromocytomas: from histology to molecular immunohistochemistry. Endocr Pathol 32:228–244. https://doi.org/10.1007/s12022-021-09675-0

Article  Google Scholar 

Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33:90–114. https://doi.org/10.1007/s12022-022-09704-6

Article  CAS  Google Scholar 

Fishbein L (2016) Pheochromocytoma and paraganglioma: Genetics, diagnosis, and treatment. Hematol Oncol Clin North Am 30:135–150. https://doi.org/10.1016/j.hoc.2015.09.006

Article  Google Scholar 

Powers JF, Korgaonkar PG, Fliedner S, Giubellino A, Pacak K, Sahagian GG, Tischler AS (2014) Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines. PLoS One 9:e87807. https://doi.org/10.1371/journal.pone.0087807

Lenders JWM, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad MH, Naruse M, Pacak K, Young WF (2014) Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 99:1915–1942. https://doi.org/10.1210/jc.2014-1498

Article  CAS  Google Scholar 

Juhlin CC, Mete O (2022) Advances in adrenal and extra-adrenal paraganglioma: Practical synopsis for pathologists. Adv Anat Pathol. https://doi.org/10.1097/PAP.0000000000000365

Article  Google Scholar 

Welander J, Andreasson A, Juhlin CC, Wiseman RW, Bäckdahl M, Höög A, Larsson C, Gimm O, Söderkvist P (2014) Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 99:E1352–1360. https://doi.org/10.1210/jc.2013-4375

Article  CAS  Google Scholar 

Buffet A, Burnichon N, Favier J, Gimenez-Roqueplo A-P (2020) An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 34:101416. https://doi.org/10.1016/j.beem.2020.101416

Stenman A, Zedenius J, Juhlin CC (2019) The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-a meta-analysis and systematic review of the literature. Cancers (Basel) 11:225. https://doi.org/10.3390/cancers11020225

Article  CAS  Google Scholar 

Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L (2020) Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab 105:e4661-4670. https://doi.org/10.1210/clinem/dgaa608

Article  Google Scholar 

Cho YY, Kwak MK, Lee S-E, Ahn SH, Kim H, Suh S, Kim B-J, Song K-H, Koh J-M, Kim JH, Lee SH (2018) A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. Surgery 164:511–517. https://doi.org/10.1016/j.surg.2018.05.001

Article  Google Scholar 

Feng F, Zhu Y, Wang X, Wu Y, Zhou W, Jin X, Zhang R, Sun F, Kasoma Z, Shen Z (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185:1583–1590. https://doi.org/10.1016/j.juro.2010.12.050

Article  Google Scholar 

Stenman A, Svahn F, Hojjat-Farsangi M, Zedenius J, Söderkvist P, Gimm O, Larsson C, Juhlin CC (2018) Molecular profiling of pheochromocytoma and abdominal paraganglioma stratified by the PASS algorithm reveals chromogranin B as associated with histologic prediction of malignant behavior. Am J Surg Pathol. https://doi.org/10.1097/PAS.0000000000001190

Article  Google Scholar 

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013

Article  CAS  Google Scholar 

Toh Y-M, Li T-K (2011) Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway. Clin Cancer Res 17:5026–5037. https://doi.org/10.1158/1078-0432.CCR-11-0235

Article  CAS  Google Scholar 

Romero A, Caldés T, Díaz-Rubio E, Martín M (2012) Topoisomerase 2 alpha: a real predictor of anthracycline efficacy? Clin Transl Oncol 14:163–168. https://doi.org/10.1007/s12094-012-0779-1

Article  CAS  Google Scholar 

Jain M, Zhang L, He M, Zhang Y-Q, Shen M, Kebebew E (2013) TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer 20:361–370. https://doi.org/10.1530/ERC-12-0403

Article  CAS  Google Scholar 

Liu T, Zhang H, Yi S, Gu L, Zhou M (2019) Mutual regulation of MDM4 and TOP2A in cancer cell proliferation. Mol Oncol 13:1047–1058. https://doi.org/10.1002/1878-0261.12457

Article  CAS  Google Scholar 

Lan J, Huang H-Y, Lee S-W, Chen T-J, Tai H-C, Hsu H-P, Chang K-Y, Li C-F (2014) TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumour Biol 35:179–187. https://doi.org/10.1007/s13277-013-1022-6

Article  CAS  Google Scholar 

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl A-C, Röske A, Eldin Elwali N, Dietel M, Denkert C (2009) Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol 22:579–588. https://doi.org/10.1038/modpathol.2009.14

Article  CAS  Google Scholar 

Su Q, Ding Q, Zhang Z, Yang Z, Qiu Y, Li X, Mo W (2020) Identification of genes associated with the metastasis of pheochromocytoma/paraganglioma based on weighted gene coexpression network analysis. Biomed Res Int 2020:3876834. https://doi.org/10.1155/2020/3876834

Article  CAS  Google Scholar 

Suh YJ, Park JH, Bilegsaikhan S-E, Lee DJ (2019) Transcriptome analysis reveals significant differences in gene expression of malignant pheochromocytoma or paraganglioma. Int J Endocrinol 2019:7014240. https://doi.org/10.1155/2019/7014240

Article  CAS  Google Scholar 

Wang X, Wang J, Lyu L, Gao X, Cai Y, Tang B (2022) Oncogenic role and potential regulatory mechanism of topoisomerase IIα in a pan-cancer analysis. Sci Rep 12:11161. https://doi.org/10.1038/s41598-022-15205-7

Article  CAS  Google Scholar 

Zhao F, Chang J, Zhao P, Wang W, Sun X, Ma X, Yin M, Wang Y, Yang Y (2022) Oncogenetic function and prognostic value of DNA topoisomerase ii alpha in human malignances: A pan-cancer analysis. Front Genet 13:856692. https://doi.org/10.3389/fgene.2022.856692

Zethoven M, Martelotto L, Pattison A, Bowen B, Balachander S, Flynn A, Rossello FJ, Hogg A, Miller JA, Frysak Z, Grimmond S, Fishbein L, Tischler AS, Gill AJ, Hicks RJ, Dahia PLM, Clifton-Bligh R, Pacak K, Tothill RW (2022) Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment. Nat Commun 13:6262. https://doi.org/10.1038/s41467-022-34011-3

Article  CAS  Google Scholar 

Gupta D, Shidham V, Holden J, Layfield L (2000) Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Mol Morphol 8:267–274

CAS  Google Scholar 

Lloyd RV, Osamura RY, Klöppel G, Rosai J, International Agency for Research on Cancer (2017) WHO classification of tumours of endocrine organs, 4th edition. International Agency for Research on Cancer, Lyon

Stenman A, Welander J, Gustavsson I, Brunaud L, Bäckdahl M, Söderkvist P, Gimm O, Juhlin CC, Larsson C (2016) HRAS mutation prevalence and associated expression patterns in pheochromocytoma. Genes Chromosomes Cancer 55:452–459. https://doi.org/10.1002/gcc.22347

Article  CAS  Google Scholar 

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo A-P, Giordano TJ, Asa SL, Tischler AS, Cancer Genome Atlas Research Network, Pacak K, Nathanson KL, Wilkerson MD (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181–193. https://doi.org/10.1016/j.ccell.2017.01.001

Article  CAS  Google Scholar 

Hellgren LS, Stenman A, Paulsson JO, Höög A, Larsson C, Zedenius J, Juhlin CC (2022) Prognostic utility of the Ki-67 labeling index in follicular thyroid tumors: a 20-year experience from a tertiary thyroid center. Endocr Pathol 33:231–242. https://doi.org/10.1007/s12022-022-09714-4

Article  CAS  Google Scholar 

Kim KY, Kim JH, Hong AR, Seong M-W, Lee KE, Kim S-J, Kim SW, Shin CS, Kim SY (2016) Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS ONE 11:e0168413. https://doi.org/10.1371/journal.pone.0168413

Juhlin CC, Stenman A, Haglund F, Clark VE, Brown TC, Baranoski J, Bilguvar K, Goh G, Welander J, Svahn F, Rubinstein JC, Caramuta S, Yasuno K, Günel M, Bäckdahl M, Gimm O, Söderkvist P, Prasad ML, Korah R, Lifton RP, Carling T (2015) Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene. Genes Chromosomes Cancer 54:542–554. https://doi.org/10.1002/gcc.22267

Article  CAS  Google Scholar 

Gong M-C, Chen W-Q, Jin Z-Q, Lyu J, Meng L-H, Wu H-Y, Chen F-H (2021) Prognostic value and significant pathway exploration associated with TOP2A involved in papillary thyroid cancer. Int J Gen Med 14:3485–3496. https://doi.org/10.2147/IJGM.S316145

Article  Google Scholar 

Chen D, Maruschke M, Hakenberg O, Zimmermann W, Stief CG, Buchner A (2017) TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology 102:265.e1-265.e7. https://doi.org/10.1016/j.urology.2016.12.050

Article  Google Scholar 

Chen T, Sun Y, Ji P, Kopetz S, Zhang W (2015) Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene 34:4019–4031. https://doi.org/10.1038/onc.2014.332

Article  CAS  Google Scholar 

Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, Teng X, Zou L, Wang Q, Jia H, Liu X, Zheng H, Hou P, Yu H, Sun Y, Zhang Z, Zhang P, Zhang L (2020) TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genomics 13:145. https://doi.org/10.1186/s12920-020-00800-2

Article  CAS  Google Scholar 

Mete O, Pakbaz S, Lerario AM, Giordano TJ, Asa SL (2021) Significance of alpha-inhibin expression in pheochromocytomas and paragangliomas. Am J Surg Pathol 45:1264–1273. https://doi.org/10.1097/PAS.0000000000001715

Article  Google Scholar 

Schovanek J, Bullova P, Tayem Y, Giubellino A, Wesley R, Lendvai N, Nölting S, Kopacek J, Frysak Z, Pommier Y, Kummar S, Pacak K (2015) Inhibitory effect of the noncamptothecin topoisomerase I inhibitor LMP-400 on female mice models and human pheochromocytoma cells. Endocrinology 156:4094–4104. https://doi.org/10.1210/en.2015-1476

Article  CAS  Google Scholar 

Arivazhagan A, Kumar DM, Sagar V, Patric IRP, Sridevi S, Thota B, Srividya MR, Prasanna K, Thennarasu K, Mondal N, Hegde AS, Chandramouli BA, Santosh V, Rao MRS, Kondaiah P, Somasundaram K (2012) Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor. J Neurooncol 107:289–297. https://doi.org/10.1007/s11060-011-0758-3

Article  CAS  Google Scholar 

Granberg D, Juhlin CC, Falhammar H (2021) Metastatic pheochromocytomas and abdominal paragangliomas. J Clin Endocrinol Metab 106:e1937–e1952. https://doi.org/10.1210/clinem/dgaa982

Article  Google Scholar